Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate ADMA Biologics, Inc. before investing.

In this article, we go over a few key elements for understanding ADMA Biologics, Inc.’s stock price such as:

• ADMA Biologics, Inc.’s current stock price and volume
• Why ADMA Biologics, Inc.’s stock price changed recently
• Upgrades and downgrades for ADMA from analysts
• ADMA’s stock price momentum as measured by its relative strength

About ADMA Biologics, Inc. (ADMA)

Before we jump into ADMA Biologics, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Want to learn more about ADMA Biologics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about ADMA Biologics, Inc..

ADMA Biologics, Inc.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, ADMA Biologics, Inc.’s stock price was $8.460.

ADMA Biologics, Inc. is down 2.42% from its previous closing price of $8.670.

During the last market session, ADMA Biologics, Inc.’s stock traded between $8.350 and $8.660. Currently, there are approximately 236.07 million shares outstanding for ADMA Biologics, Inc..

ADMA Biologics, Inc.’s price-earnings (P/E) ratio is currently at 12.7, which is low compared to the Biotechnology industry median of 18.6. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

ADMA Biologics, Inc. Stock Price History

ADMA Biologics, Inc.’s (ADMA) price is currently up 1.08% so far this month.

During the month of July, ADMA Biologics, Inc.’s stock price has reached a high of $9.330 and a low of $8.165.

Over the last year, ADMA Biologics, Inc. has hit prices as high as $20.458 and as low as $7.210. Year to date, ADMA Biologics, Inc.’s stock is down 53.62%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused ADMA Biologics, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 30, 2026, there were 0 analysts who downgraded ADMA Biologics, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate ADMA Biologics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on ADMA Biologics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

ADMA Biologics, Inc.’s current valuation based on AAII’s Value Grade is a D, which means it is considered to be Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about ADMA Biologics, Inc. (ADMA) by visiting AAII Stock Evaluator.

Relative Price Strength of ADMA Biologics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 30, 2026, ADMA Biologics, Inc. has a weighted four-quarter relative price strength of -18.50%, which translates to a Momentum Score of 13 and is considered to be Very Weak.

Want to learn more about how ADMA Biologics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

ADMA Biologics, Inc. Stock Price: Bottom Line

As of July 31, 2026, ADMA Biologics, Inc.’s stock price is $8.460, which is down 2.42% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like ADMA Biologics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.